Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Prasad, J. Lenzer, D. Newman (2016)
Why cancer screening has never been shown to “save lives”—and what we can do about itBMJ : British Medical Journal, 352
J. Warren, C. Klabunde, D. Schrag, P. Bach, G. Riley (2002)
Overview of the SEER-Medicare Data
V. Prasad (2016)
Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?Medical hypotheses, 93
W. Shipley, W. Seiferheld, H. Lukka, P. Major, N. Heney, D. Grignon, O. Sartor, M. Patel, J. Bahary, A. Zietman, T. Pisansky, K. Zeitzer, C. Lawton, F. Feng, R. Lovett, A. Balogh, L. Souhami, S. Rosenthal, K. Kerlin, J. Dignam, S. Pugh, H. Sandler (2017)
Radiation with or without Antiandrogen Therapy in Recurrent Prostate CancerThe New England Journal of Medicine, 376
G. Andriole, E. Crawford, R. Grubb, S. Buys, D. Chia, T. Church, M. Fouad, C. Isaacs, P. Kvale, D. Reding, J. Weissfeld, L. Yokochi, B. O'Brien, L. Ragard, J. Clapp, J. Rathmell, T. Riley, A. Hsing, G. Izmirlian, P. Pinsky, B. Kramer, A. Miller, J. Gohagan, P. Prorok (2012)
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.Journal of the National Cancer Institute, 104 2
R. German, A. Fink, Melonie Heron, S. Stewart, Chris Johnson, J. Finch, Daixin Yin (2011)
The accuracy of cancer mortality statistics based on death certificates in the United States.Cancer epidemiology, 35 2
C. Fitzmaurice, T. Akinyemiju, F. Lami, Tahiya Alam, R. Alizadeh-Navaei, Christine Allen, U. Alsharif, N. Alvis-Guzmán, E. Amini, B. Anderson, O. Aremu, A. Artaman, S. Asgedom, Reza Assadi, T. Atey, L. Ávila-Burgos, A. Awasthi, Huda Saleem, A. Barać, James Bennett, I. Benseñor, N. Bhakta, H. Brenner, Lucero Cahuana-Hurtado, C. Castañeda-Orjuela, F. Catalá-López, J. Choi, D. Christopher, Sheng-Chia Chung, M. Curado, L. Dandona, R. Dandona, J. Neves, Subhojit Dey, S. Dharmaratne, D. Doku, T. Driscoll, M. Dubey, H. Ebrahimi, Dumessa Edessa, Z. El-Khatib, A. Endries, F. Fischer, Lisa Force, Kyle Foreman, S. Gebrehiwot, S. Gopalani, G. Grosso, Rahul Gupta, B. Gyawali, R. Hamadeh, S. Hamidi, James Harvey, H. Hassen, R. Hay, S. Hay, B. Heibati, Molla Hiluf, N. Horita, H. Hosgood, O Ilesanmi, K. Innos, F. Islami, M. Jakovljevic, Sarah Johnson, J. Jonas, A. Kasaeian, T. Kassa, Y. Khader, E. Khan, G. Khan, Y. Khang, Mohammad Khosravi, J. Khubchandani, J. Kopec, G. Kumar, Michael Kutz, D. Lad, A. Lafranconi, Q. Lan, Yirga Legesse, J. Leigh, S. Linn, R. Lunevicius, A. Majeed, R. Malekzadeh, D. Malta, L. Mantovani, B. McMahon, T. Meier, Y. Melaku, M. Melku, P. Memiah, W. Mendoza, T. Meretoja, H. Mezgebe, T. Miller, S. Mohammed, A. Mokdad, M. Moosazadeh, P. Moraga, Seyyed Mousavi, V. Nangia, C. Nguyen, V. Nong, F. Ogbo, A. Olagunju, Mahesh Pa, Eun‐Kee Park, Tejas Patel, David Pereira, F. Pishgar, M. Postma, F. Pourmalek, M. Qorbani, Anwar Rafay, S. Rawaf, D. Rawaf, G. Roshandel, S. Safiri, H. Salimzadeh, J. Sanabria, M. Milićević, B. Sartorius, Maheswar Satpathy, S. Sepanlou, K. Shackelford, M. Shaikh, M. Sharif-Alhoseini, Jun She, Min-Jeong Shin, I. Shiue, M. Shrime, A. Sinke, M. Sisay, Amber Sligar, M. Sufiyan, Bryan Sykes, R. Tabarés-Seisdedos, G. Tessema, R. Topor-Madry, T. Tran, B. Tran, K. Ukwaja, V. Vlassov, S. Vollset, E. Weiderpass, H. Williams, N. Yimer, N. Yonemoto, M. Younis, C. Murray, M. Naghavi (2018)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016JAMA Oncology, 4
M. Ebell, M. Bentivegna, C. Hulme (2020)
Cancer-Specific Mortality, All-Cause Mortality, and Overdiagnosis in Lung Cancer Screening Trials: A Meta-AnalysisThe Annals of Family Medicine, 18
F. Schröder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Luján, H. Lilja, M. Zappa, L. Denis, F. Recker, A. Berenguer, L. Määttänen, C. Bangma, G. Aus, A. Villers, X. Rébillard, T. Kwast, B. Blijenberg, S. Moss, H. Koning, A. Auvinen (2009)
Screening and prostate-cancer mortality in a randomized European study.The New England journal of medicine, 360 13
J. Warren, C. Klabunde, D. Schrag, P. Bach, G. Riley (2002)
Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly PopulationMedical Care, 40
A. Aizer, Ming-Hui Chen, E. McCarthy, Mallika Mendu, S. Koo, T. Wilhite, Powell Graham, T. Choueiri, K. Hoffman, N. Martin, Jim Hu, P. Nguyen (2013)
Marital status and survival in patients with cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 31
V. Prasad, M. Diener-West (2015)
Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?Canadian Medical Association Journal, 187
S. Duffy, D. Vulkan, H. Cuckle, D. Parmar, Shama Sheikh, Robert Smith, A. Evans, O. Blyuss, L. Johns, I. Ellis, J. Myles, P. Sasieni, S. Moss (2020)
Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trialThe Lancet. Oncology, 21
D. Sarfati, T. Blakely, N. Pearce (2010)
Measuring cancer survival in populations: relative survival vs cancer-specific survival.International journal of epidemiology, 39 2
N. Saquib, J. Saquib, J. Ioannidis (2015)
Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials.International journal of epidemiology, 44 1
R. Dess, Holly Hartman, B. Mahal, P. Soni, W. Jackson, M. Cooperberg, C. Amling, W. Aronson, C. Kane, M. Terris, Z. Zumsteg, S. Butler, J. Osborne, T. Morgan, R. Mehra, S. Salami, A. Kishan, Chenyang Wang, E. Schaeffer, M. Roach, T. Pisansky, W. Shipley, S. Freedland, H. Sandler, S. Halabi, F. Feng, J. Dignam, P. Nguyen, M. Schipper, D. Spratt (2019)
Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.JAMA oncology
G. Sandblom, E. Varenhorst, J. Rosell, O. Löfman, P. Carlsson (2011)
Randomised prostate cancer screening trial: 20 year follow-upThe BMJ, 342
Jennifer Lund, L. Harlan, K. Yabroff, Joan Warren (2010)
Should Cause of Death From the Death Certificate Be Used to Examine Cancer-Specific Survival? A Study of Patients With Distant Stage DiseaseCancer Investigation, 28
K. Doll, A. Rademaker, J. Sosa (2018)
Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) DatabaseJAMA Surgery, 153
M. Sun, Q. Trinh (2016)
A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and veritiesBJU International, 117
H. Koning, C. Aalst, P. Jong, E. Scholten, K. Nackaerts, M. Heuvelmans, J. Lammers, C. Weenink, U. Yousaf-Khan, N. Horeweg, S. Westeinde, M. Prokop, W. Mali, F. Hoesein, P. Ooijen, J. Aerts, M. Bakker, E. Thunnissen, J. Verschakelen, R. Vliegenthart, J. Walter, K. Haaf, H. Groen, M. Oudkerk (2020)
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.The New England journal of medicine
Henry Park, S. Lloyd, R. Decker, L. Wilson, James Yu (2012)
Overview of the Surveillance, Epidemiology, and End Results database: evolution, data variables, and quality assurance.Current problems in cancer, 36 4
J. Dignam, Lan Huang, L. Ries, M. Reichman, A. Mariotto, E. Feuer (2009)
Estimating breast cancer‐specific and other‐cause mortality in clinical trial and population‐based cancer registry cohortsCancer, 115
L. Nyström, I. Andersson, N. Bjurstam, J. Frisell, B. Nordenskjöld, L. Rutqvist (2002)
Long-term effects of mammography screening: updated overview of the Swedish randomised trialsThe Lancet, 359
F. Schröder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Luján, H. Lilja, M. Zappa, L. Denis, F. Recker, Á. Páez, L. Määttänen, C. Bangma, G. Aus, S. Carlsson, A. Villers, X. Rébillard, T. Kwast, P. Kujala, B. Blijenberg, U. Stenman, A. Huber, K. Taari, M. Hakama, S. Moss, H. Koning, A. Auvinen (2012)
Prostate-cancer mortality at 11 years of follow-up.The New England journal of medicine, 366 11
W. Black, D. Haggstrom, H. Welch (2002)
All-cause mortality in randomized trials of cancer screening.Journal of the National Cancer Institute, 94 3
M. Pinquart, P. Duberstein (2010)
Associations of social networks with cancer mortality: a meta-analysis.Critical reviews in oncology/hematology, 75 2
Objectives: Deaths from an unknown cause are difficult to adjudicate and oncologic studies of comparative effectiveness often demonstrate inconsistencies in incorporating these deaths and competing events (eg, heart disease and stroke) in their analyses. In this study, we identify cancer patients most at risk for death of an unknown cause. Methods: This retrospective, population-based study used cancer registry data from the Surveillance, Epidemiology, and End Results database (1992-2015). The absolute rate of unknown causes of death (COD) cases stratified by sex, marital status, race, treatment, and cancer site were calculated and a multivariable logistic regression model was applied to obtain adjusted odds ratios with 95% CIs. Results: Out of 7,154,779 cancer patients across 22 cancer subtypes extracted from Surveillance, Epidemiology, and End Results, 3,448,927 died during follow-up and 276,068 (7.4%) of these deaths were from unknown causes. Patients with an unknown COD had a shorter mean survival time compared with patients with known COD (36.3 vs 65.7 mo, P < 0.001). The contribution of unknown COD to total mortality was highest in patients with more indolent cancers (eg, prostate [12.7%], thyroid [12.3%], breast [10.7%]) and longer follow-up (eg, >5 to 10 y). One, 3, and 5-year cancer-specific survival (CSS) calculations including unknown COD were significantly decreased compared with CSS estimates excluding cancer patients with unknown COD. Conclusion: Of the patients, 7.4% died of unknown causes during follow-up and the proportion of death was higher with longer follow-up and among more indolent cancers. The attribution of high percentages of unknown COD to cancer or non-cancer causes could impact population-based cancer registry studies or clinical trial outcomes with respect to measures involving CSS and mortality.
American Journal of Clinical Oncology – Wolters Kluwer Health
Published: Jun 11, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.